Ask Anything
LIVEESC Congress 2026Munich · Aug 28-31 · Hot Line trials and the live discussion from MunichOpen the hub→Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
cohort · n=1,1256 mentions
SEP 2ManzanaresJACC Advances
Elevated HFpEF-ABA scores linked to ~141% higher risk of death or HF hospitalization.
The HFpEF-ABA score provides moderate diagnostic discrimination for HFpEF and identifies outpatients with type 2 diabetes at high risk for adverse clinical outcomes.
VSDr. Varun Sundaram
Heart Failure Cardiologist, University Hospitals Harrington Heart & Vascular Institute
With the new, simple scoring system, 'We are able to screen and effectively identify patients with a high probability of HFpEF at the population level.' We're tapping into an opportunity to elevate the standard of care, and it will change the paradigm for diagnosis for better identification of HFpEF at the community level.
RCT · n=3202 mentionsTrending on X
SEP 1凌天佑EP Europace
First-line cryoballoon ablation cuts atrial tachyarrhythmia recurrence ~58% versus antiarrhythmic drugs.
Supports first-line cryoballoon ablation in treatment-naive persistent AF; extends randomized evidence from paroxysmal populations.
PHDr. Peter Steen Hansen
Cardiologist and Electrophysiologist, Rytmedoktor
For years, we have known that ablation is a safe and effective treatment for paroxysmal atrial fibrillation – episodes that come and go. However, there has been more skepticism regarding persistent atrial fibrillation, which does not resolve spontaneously. Several studies have shown that outcomes are generally less favorable in this group.
cohort · n=1,274,8631 mentionsTrending on X
SEP 2VermaCirculation Heart Failure
Hospital GWTG-HF participation is linked to ~0.15-point higher 90-day post-discharge GDMT scores versus non-participating hospitals.
GWTG-HF participation was associated with higher post-discharge GDMT scores; leaves open whether quality programs improve outcomes in HFrEF.
cohort · n=1551 mentions
SEP 1LiJournal of Cardiovascular Development and Disease
CT-derived EAT volume fails to improve CAD discrimination beyond conventional risk factors in adults ≥80 years.
EAT volume adds no CAD discrimination value in patients ≥80 years; leaves open its utility in younger cohorts or for other endpoints.
cohort · n=2,7031 mentionsTrending on X
SEP 1KatoCirculation Journal
A ≥25% increase in NT-proBNP over 5 years is linked to ~73% higher all-cause mortality.
May aid risk stratification via serial NT-proBNP in Asian adults; extends trajectory data but remains hypothesis-generating.
RCT2 mentions
SEP 2WadhwaEuropean Spine Journal
Cervical disc arthroplasty RCTs report ~300% higher ACDF reoperation rates than observational studies at mid-term.
Systematic review and meta-analysis reveals higher ACDF reoperation and pseudoarthrosis rates in CDA trials versus observational cohorts, suggesting study design impacts reported fusion outcomes.
RCT · n=402 mentions
SEP 2Ali4
Center-based Phase II cardiac rehabilitation yields greater quality of life improvements than home-based rehabilitation.
Center-based Phase II rehab may be prioritized post-CABG for greater QoL gains; extends RCT evidence favoring supervised over home-based programs.
RCT · n=1125 mentionsTrending on X
SEP 2YanClinical Journal of the American Society of Nephrology
Henagliflozin reduces LVMI by ~5 g/m2 vs placebo in dialysis patients with HFpEF.
Supports henagliflozin to reduce LV mass in dialysis HFpEF; extends SGLT2 inhibitor evidence to end-stage kidney disease.
meta-analysis · n=9962 mentions
SEP 1EmaraCardiology in Review
Dronedarone shows no benefit over amiodarone for preventing AF recurrence after catheter ablation.
May guide post-ablation agent selection by safety profile; leaves open confirmation in dedicated randomized trials.
meta-analysis · n=3191 mentions
SEP 1KeshtegarArtery Research
Melatonin is linked to a borderline PWV reduction below the minimal clinically important difference.
Melatonin lacks clinically meaningful PWV effects; confirms limited impact on arterial stiffness and leaves BP benefits open to targeted trials.
